Movement Alert｜Abivax S.A. Rises 5.06% in Regular Trading, Institutional Bullish Views and Pipeline Progress Drive Rebound

Market Focus09-17 23:40

On September 17, Abivax S.A. rose 5.06% in regular trading, trading at 107.45 USD/share, with Turnover of $45.61 million. The stock had previously declined over 5% on September 15 amid concerns over an upcoming earnings report projecting a 43% year-over-year revenue decline, but rebounded as institutional optimism and core pipeline milestones reasserted market confidence.

On the news front, Abivax has reaffirmed its plan to submit its first New Drug Application for obefazimod in the treatment of moderately to severely active ulcerative colitis before year-end. Morgan Stanley raised its price target to $180 from $132 while maintaining an Overweight rating, citing experts being unanimously positive on obefazimod's efficacy profile, particularly on endoscopic measures. Additionally, the company recently closed a $920 million ADS offering, generating approximately $874.1 million in net proceeds, which management expects to fund operations into Q4 of 2029, providing a substantial cash runway.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1125721937?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-17 23:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1125721937","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Abivax S.A. Rises 5.06% in Regular Trading, Institutional Bullish Views and Pipeline Progress Drive Rebound","media":"Market Focus","content":"<p><p>On September 17, Abivax S.A. rose 5.06% in regular trading, trading at 107.45 USD/share, with Turnover of $45.61 million. The stock had previously declined over 5% on September 15 amid concerns over an upcoming earnings report projecting a 43% year-over-year revenue decline, but rebounded as institutional optimism and core pipeline milestones reasserted market confidence.</p><p>On the news front, Abivax has reaffirmed its plan to submit its first New Drug Application for obefazimod in the treatment of moderately to severely active ulcerative colitis before year-end. Morgan Stanley raised its price target to $180 from $132 while maintaining an Overweight rating, citing experts being unanimously positive on obefazimod's efficacy profile, particularly on endoscopic measures. Additionally, the company recently closed a $920 million ADS offering, generating approximately $874.1 million in net proceeds, which management expects to fund operations into Q4 of 2029, providing a substantial cash runway.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Abivax S.A. Rises 5.06% in Regular Trading, Institutional Bullish Views and Pipeline Progress Drive Rebound</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Abivax S.A. Rises 5.06% in Regular Trading, Institutional Bullish Views and Pipeline Progress Drive Rebound\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-09-17 23:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On September 17, Abivax S.A. rose 5.06% in regular trading, trading at 107.45 USD/share, with Turnover of $45.61 million. The stock had previously declined over 5% on September 15 amid concerns over an upcoming earnings report projecting a 43% year-over-year revenue decline, but rebounded as institutional optimism and core pipeline milestones reasserted market confidence.</p><p>On the news front, Abivax has reaffirmed its plan to submit its first New Drug Application for obefazimod in the treatment of moderately to severely active ulcerative colitis before year-end. Morgan Stanley raised its price target to $180 from $132 while maintaining an Overweight rating, citing experts being unanimously positive on obefazimod's efficacy profile, particularly on endoscopic measures. Additionally, the company recently closed a $920 million ADS offering, generating approximately $874.1 million in net proceeds, which management expects to fund operations into Q4 of 2029, providing a substantial cash runway.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ABVX","symbol_name":"Abivax S.A.","start_time":0,"source_url":"","article_id":"1125721937","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1125721937","pubTimestamp":1789659618,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On September 17, Abivax S.A. rose 5.06% in regular trading, trading at 107.45 USD/share, with Turnover of $45.61 million. The stock had previously declined over 5% on September 15 amid concerns over...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ABVX":"Abivax S.A."},"translate_title":"走势警报|Abivax S.A. 常规交易中上涨 5.06%，机构看涨观点和管道进展推动反弹","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABVX":1},"content_text":"On September 17, Abivax S.A. rose 5.06% in regular trading, trading at 107.45 USD/share, with Turnover of $45.61 million. The stock had previously declined over 5% on September 15 amid concerns over an upcoming earnings report projecting a 43% year-over-year revenue decline, but rebounded as institutional optimism and core pipeline milestones reasserted market confidence.On the news front, Abivax has reaffirmed its plan to submit its first New Drug Application for obefazimod in the treatment of moderately to severely active ulcerative colitis before year-end. Morgan Stanley raised its price target to $180 from $132 while maintaining an Overweight rating, citing experts being unanimously positive on obefazimod's efficacy profile, particularly on endoscopic measures. Additionally, the company recently closed a $920 million ADS offering, generating approximately $874.1 million in net proceeds, which management expects to fund operations into Q4 of 2029, providing a substantial cash runway.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1125721937","isCrawlerRequest":true}